ATE266655T1 - Dibenzopyrane als glucocorticoid-rezeptor- antagonisten für die behandlung von zuckerkrankheit - Google Patents

Dibenzopyrane als glucocorticoid-rezeptor- antagonisten für die behandlung von zuckerkrankheit

Info

Publication number
ATE266655T1
ATE266655T1 AT00959835T AT00959835T ATE266655T1 AT E266655 T1 ATE266655 T1 AT E266655T1 AT 00959835 T AT00959835 T AT 00959835T AT 00959835 T AT00959835 T AT 00959835T AT E266655 T1 ATE266655 T1 AT E266655T1
Authority
AT
Austria
Prior art keywords
dibenzopyrane
treatment
receptor antagonists
glucocorticoid receptor
subject disease
Prior art date
Application number
AT00959835T
Other languages
English (en)
Inventor
Philip R Kym
Benjamin C Lane
John K Pratt
Geldern Tom Von
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE266655T1 publication Critical patent/ATE266655T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
AT00959835T 1999-09-01 2000-09-01 Dibenzopyrane als glucocorticoid-rezeptor- antagonisten für die behandlung von zuckerkrankheit ATE266655T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38825199A 1999-09-01 1999-09-01
PCT/US2000/024234 WO2001016128A1 (en) 1999-09-01 2000-09-01 Dibenzopyrans as glucocorticoid receptor antagonists for treatment of diabetes

Publications (1)

Publication Number Publication Date
ATE266655T1 true ATE266655T1 (de) 2004-05-15

Family

ID=23533319

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00959835T ATE266655T1 (de) 1999-09-01 2000-09-01 Dibenzopyrane als glucocorticoid-rezeptor- antagonisten für die behandlung von zuckerkrankheit

Country Status (15)

Country Link
EP (1) EP1208095B1 (de)
JP (1) JP2003508393A (de)
AR (1) AR034096A1 (de)
AT (1) ATE266655T1 (de)
AU (1) AU7109000A (de)
BR (1) BR0009320A (de)
CA (1) CA2381239A1 (de)
CO (1) CO5180649A1 (de)
DE (1) DE60010722T2 (de)
DK (1) DK1208095T3 (de)
ES (1) ES2220529T3 (de)
HK (1) HK1047580B (de)
MX (1) MXPA02002110A (de)
PT (1) PT1208095E (de)
WO (1) WO2001016128A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593480B2 (en) * 1999-09-01 2003-07-15 Abbott Laboratories Glucocorticoid receptor antagonists for treatment of diabetes
US7235662B2 (en) 2003-06-11 2007-06-26 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
JP5281291B2 (ja) 2005-01-10 2013-09-04 グラクソ グループ リミテッド 新規化合物
MY145281A (en) 2005-03-25 2012-01-13 Glaxo Group Ltd Novel compounds
UY29439A1 (es) 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
PE20071068A1 (es) 2005-12-20 2007-12-13 Glaxo Group Ltd Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3
EA200801997A1 (ru) 2006-04-20 2009-04-28 Глаксо Груп Лимитед Новые соединения
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
TW200820977A (en) 2006-08-08 2008-05-16 Organon Nv Use of glucocorticoid receptor antagonists for treatment of infectious conditions
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
JP5791500B2 (ja) 2008-05-23 2015-10-07 パンミラ ファーマシューティカルズ，エルエルシー． ５−リポキシゲナーゼ活性化タンパク質阻害剤
WO2009147190A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
EP2280946B1 (de) 2008-06-05 2016-02-10 Glaxo Group Limited Als p13-kinasehemmer nutzbare 4-carboxamid-indazol-derivate
ES2745628T3 (es) 2008-11-07 2020-03-03 Univ Sheffield Medicamento y método de diagnóstico
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
US8524751B2 (en) 2009-03-09 2013-09-03 GlaxoSmithKline Intellecutual Property Development 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
JP2012520845A (ja) 2009-03-17 2012-09-10 グラクソ グループ リミテッド Ｉｔｋ阻害剤として使用されるピリミジン誘導体
US20120035247A1 (en) 2009-03-19 2012-02-09 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA)
JP2012520683A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた結合組織増殖因子（ＣＴＧＦ）遺伝子発現のＲＮＡ干渉媒介性阻害
AU2010226604A1 (en) 2009-03-19 2011-10-13 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of BTB and CNC homology 1, basic leucine zipper transcription factor 1 (Bach 1) gene expression using short interfering nucleic acid (siNA) sequence listing
US20120029054A1 (en) 2009-03-19 2012-02-02 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
WO2010111490A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2411517A2 (de) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. Rna-interferenz-vermittelte hemmung der genexpression von icam-1 (intercellular adhesion molecule 1) unter verwendung von sina (short interfering nucleic acid)
US20120022142A1 (en) 2009-03-27 2012-01-26 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2010111468A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
US20120010272A1 (en) 2009-03-27 2012-01-12 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2010122088A1 (en) 2009-04-24 2010-10-28 Glaxo Group Limited Pyrazole and triazole carboxamides as crac channel inhibitors
US8399436B2 (en) 2009-04-24 2013-03-19 Glaxo Group Limited N-pyrazolyl carboxamides as CRAC channel inhibitors
RS53830B1 (sr) 2009-04-30 2015-06-30 Glaxo Group Limited Indazoli supstituisani oksazolom kao inhibitori pi3-kinaze
EP2507231A1 (de) 2009-12-03 2012-10-10 Glaxo Group Limited Indazolderivate als pi3-kinaseinhibitoren
WO2011067365A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
WO2011067364A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Novel compounds
US20120272951A1 (en) 2009-12-16 2012-11-01 3M Innovative Properties Company Formulations and methods for controlling mdi particle size delivery
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
EP2613781B1 (de) 2010-09-08 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Indazolderivate für die behandlung von influenzavireninfektionen
HRP20151017T1 (hr) 2010-09-08 2015-10-23 Glaxosmithkline Intellectual Property Development Limited Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2-(metiloksi)-3-piridinil]metansulfonamida
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
JP5795643B2 (ja) 2010-10-21 2015-10-14 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ アレルギー性状態、免疫性状態及び炎症性状態に作用するピラゾール化合物
WO2012052459A1 (en) 2010-10-21 2012-04-26 Glaxo Group Limited Pyrazole compounds acting against allergic, inflammatory and immune disorders
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
US20140005188A1 (en) 2011-03-11 2014-01-02 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
KR20160060100A (ko) 2013-09-22 2016-05-27 칼리토르 사이언시즈, 엘엘씨 치환된 아미노피리미딘 화합물 및 이용 방법
EP3057588A1 (de) 2013-10-17 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Pi3k-hemmers zur behandlung von atemwegserkrankungen
KR20160062179A (ko) 2013-10-17 2016-06-01 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 호흡기 질병의 치료를 위한 ｐｉ３ｋ 억제제
US9399637B2 (en) 2014-03-28 2016-07-26 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
WO2015173701A2 (en) 2014-05-12 2015-11-19 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions for treating infectious diseases
EP3347097B1 (de) 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituierte aminopyrimidin-derivate als modulatoren der kinasen jak, flt3 und aurora
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
EP3497100A1 (de) 2016-08-08 2019-06-19 GlaxoSmithKline Intellectual Property Development Limited Chemische verbindungen
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
WO2019099311A1 (en) 2017-11-19 2019-05-23 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
CA3173172A1 (en) 2020-03-26 2021-09-30 Christopher D. Kane Cathepsin inhibitors for preventing or treating viral infections

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2091721B (en) * 1980-10-20 1984-02-15 Erba Farmitalia 6-substituted 6h-dibezo(b,d)pyran derivatives and process for their preparation
KR20010040935A (ko) * 1998-02-13 2001-05-15 스티븐 에프. 웨인스톡 글루코코르티코이드 선택적인 소염제

Also Published As

Publication number Publication date
CA2381239A1 (en) 2001-03-08
AU7109000A (en) 2001-03-26
DE60010722T2 (de) 2005-05-12
JP2003508393A (ja) 2003-03-04
ES2220529T3 (es) 2004-12-16
AR034096A1 (es) 2004-02-04
EP1208095A1 (de) 2002-05-29
WO2001016128A1 (en) 2001-03-08
CO5180649A1 (es) 2002-07-30
HK1047580A1 (en) 2003-02-28
DK1208095T3 (da) 2004-09-20
HK1047580B (en) 2005-04-01
DE60010722D1 (de) 2004-06-17
EP1208095B1 (de) 2004-05-12
PT1208095E (pt) 2004-09-30
BR0009320A (pt) 2002-02-05
MXPA02002110A (es) 2002-11-07

Similar Documents

Publication Publication Date Title
DE60010722D1 (de) Dibenzopyrane als glucocorticoid-rezeptor-antagonisten für die behandlung von zuckerkrankheit
ATE304530T1 (de) Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen
ATE551340T1 (de) Azabicyclisch- substituierte annelierte heteroaryl-verbinungen für die behandlung von krankheiten
ATE374182T1 (de) Selektive agonisten des ep4 rezeptors für die behandlung von osteoporose
DE60108754D1 (de) Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
DE60204951D1 (de) Ccr5 antagonisten verwendbar für die behandlung von aids
EP1165110A4 (de) Antagoniste von hmg1 zur behandlung von entzündungskonditionen
ATE345331T1 (de) Verbindungen verwendbar für die behandlung von entzündungskrankheiten
TR200102021T2 (tr) TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
DZ2618A1 (fr) Emploi des antagonistes des récepteurs de 5-HT3 dans le traitement de la colopathie.
DE69927823T2 (de) Hydrogel für die therapeutische behandlung von aneurysmas
ATE374196T1 (de) Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen
ATE312117T1 (de) Verbindungen für die behandlung von ischämie
ATE441417T1 (de) Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
ATE308997T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
DE60032905D1 (de) Selektive iglur5 rezeptorantagonisten zur behandlung der migräne
ATE286895T1 (de) Sulfonyl-pyrrolidinderivate geeignet für die behandlung von neurologischen krankheiten
ATE396202T1 (de) Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
ATE502642T1 (de) Kombinationen für die behandlung von immun- entzündlichen erkrankungen
ATE422498T1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
ATE260278T1 (de) 5ht1 rezeptor antagonisten und ihre verwendung für die behandlung von depression
DE60201440D1 (de) Aryl-8-azabicyclo[3.2.1]octanes für die behandlung von depression
ATE300531T1 (de) Isonipecotamide zur behandlung von integrin vermittelten störungen
DE60133596D1 (de) S-Methyl-Dihydro-Ziprasidone für die Behandlung von Schizophrenie

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1208095

Country of ref document: EP

REN Ceased due to non-payment of the annual fee